Japan's iPS cell therapies inch toward global approval
Japan's regulators have given a panel recommendation toward conditional, time-limited approval of treatments using induced pluripotent stem (iPS) cells, a big step that's been two decades in the making.
On February 19, a regulatory panel gave a conditional go-ahead for Amchepry (developed with Racthera) for Parkinson's disease, and for ReHeart for severe heart failure, offering hope where options were limited.
Amchepry and ReHeart
Amchepry (developed by Sumitomo Pharma in collaboration with RACTHERA) is designed to help people with Parkinson's by transplanting lab-grown dopaminergic neural progenitor cells into the brain to improve motor function.
ReHeart uses sheets of heart muscle cells made from iPS cells to repair damaged hearts.
First of their kind
These would be the first iPS cell therapies to receive regulatory approval worldwide if final authorization is granted.
While they still need more long-term data before full approval, this move could open doors for treating diseases that used to have no real solutions and bring cutting-edge science straight to patients who need it most.